Personalis Advances Lung Cancer Detection with Ultra-Sensitive ctDNA Testing Breakthrough

Breakthrough in Early Lung Cancer Detection Using Ultra-Sensitive ctDNA Testing

Personalis, Inc. is making waves in the oncology landscape through its collaboration with Professor Charles Swanton and his research team at the Francis Crick Institute and University College London. Their joint efforts culminate in a significant study published in Nature Medicine, focusing on the TRACERx lung cancer study that showcases the capabilities of Personalis’ NeXT Personal®, an ultra-sensitive test for detecting circulating tumor DNA (ctDNA) in the blood of cancer patients. Funded by Cancer Research UK, the trial examines pre-operative blood samples from 171 patients diagnosed with early-stage non-small cell lung cancer (NSCLC), revealing groundbreaking results that could revolutionize cancer care.

The study highlights the impressive sensitivity of NeXT Personal, achieving a remarkable 100% detection rate in non-adenocarcinomas and an 81% detection rate in the more complex lung adenocarcinoma subtype. These findings indicate that ctDNA levels present prior to surgical intervention serve as critical prognostic indicators for patient outcomes. Specifically, patients with early-stage lung adenocarcinoma who test negative for ctDNA exhibit a perfect five-year survival rate, while those who test positive face a significantly elevated risk of disease recurrence. The data emphasizes that even patients with low ctDNA levels—below 80 parts per million (PPM)—are at considerable risk, reinforcing the necessity for accurate ctDNA testing in the management of lung cancer.

Dr. Charles Swanton, a leading researcher involved in the study, notes the transformative potential of ctDNA tests in tailoring cancer treatments to individual patients. Richard Chen, MD, Chief Medical Officer at Personalis, echoes this sentiment, stressing the clinical significance of early-stage detection through advanced testing methods. The innovative NeXT Personal assay utilizes whole-genome sequencing to craft a bespoke blood test that identifies a unique signature of approximately 1,800 variants, pushing the boundaries of detection sensitivity to as low as ~1 PPM of ctDNA. Given that lung cancer ranks as the second most prevalent cancer in the U.S.—with projections of 238,340 new cases and 127,070 fatalities—the implications of this research could profoundly impact lung cancer management protocols and bolster submissions for Medicare coverage of the NeXT Personal Dx test.

In addition to the promising findings, the study’s outcomes may catalyze a shift in how early-stage lung cancer is monitored and treated. The ability to detect ctDNA with such precision not only enhances prognostic assessments but also lays the groundwork for a more personalized approach to cancer therapy. As the healthcare community gains insights from these findings, the integration of NeXT Personal testing into routine clinical practice could pave the way for improved survival rates and quality of life for lung cancer patients.